TELA Bio, Inc.TELAEarnings & Financial Report
Nasdaq
TELA Q3 2025 Key Financial Metrics
Revenue
$20.7M
Gross Profit
$14.0M
Operating Profit
$-7.6M
Net Profit
$-8.6M
Gross Margin
67.5%
Operating Margin
-36.5%
Net Margin
-41.6%
YoY Growth
9.1%
EPS
$-0.19
Financial Flow
TELA Bio, Inc. Q3 2025 Financial Summary
TELA Bio, Inc. reported revenue of $20.7M for Q3 2025, with a net profit of $-8.6M (-41.6% margin). Cost of goods sold was $6.7M, operating expenses totaled $21.5M.
Key Financial Metrics
| Total Revenue | $20.7M |
|---|---|
| Net Profit | $-8.6M |
| Gross Margin | 67.5% |
| Operating Margin | -36.5% |
| Report Period | Q3 2025 |
TELA Bio, Inc. Annual Revenue by Year
TELA Bio, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $69.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $69.3M |
| 2023 | $58.5M |
| 2022 | $41.4M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.0M | $16.6M | $16.1M | $19.0M | $17.6M | $18.5M | $20.2M | $20.7M |
| YoY Growth | 46.3% | 39.4% | 11.0% | 25.9% | 3.8% | 11.5% | 25.5% | 9.1% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $78.0M | $71.8M | $60.2M | $53.0M | $86.6M | $77.3M | $67.5M | $61.6M |
| Liabilities | $59.2M | $57.5M | $57.3M | $59.3M | $58.1M | $59.1M | $58.4M | $60.0M |
| Equity | $18.9M | $14.4M | $2.9M | $-6.3M | $28.5M | $18.1M | $9.2M | $1.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-11.1M | $-14.4M | $-10.7M | $-9.0M | $-7.5M | $-9.7M | $-7.9M | $-5.7M |